Court Square Group
Driving Efficiency in Clinical Operations with AI Solutions

Court Square Group, a leader in life sciences technology, is transforming clinical operations through the innovative application of artificial intelligence (AI).

With over three decades of experience in the pharmaceutical and biotechnology sectors, Court Square Group focuses on providing practical AI solutions designed to streamline operations, reduce costs, and enhance the overall efficiency of clinical trials. Leading this transformative effort is Keith Parent, CEO of Court Square Group, who emphasizes that the company’s mission is to offer solutions rooted in real-world applications rather than being driven by the current hype surrounding AI. He explains that while there is significant excitement around AI, court Square Group’s approach is centered on solving concrete problems within clinical operations.

“We aim to create tools that save time and make jobs easier, not just tools that sound exciting in theory,” says Parent.

He underscores the importance of practical AI applications that address the challenges faced by professionals in clinical research. This pragmatic mindset has guided the development of several AI-powered solutions at court Square Group, all aimed at optimizing the labor-intensive aspects of clinical trials.

One such innovation is the company’s AI-driven Trial Master File (TMF) auto-classification tool. Managing a TMF, which contains all essential documents related to a clinical trial, is a time-consuming process typically involving multiple human checkpoints. Clinical research associates and quality assurance staff spend significant time opening, reading, and categorizing documents to ensure compliance. The manual nature of this work makes it prone to errors and delays. court Square Group’s TMF auto-classification tool addresses this challenge by employing AI to read and classify documents while still providing for human final approval. This reduces the total time and human effort required.

The tool leverages machine learning to assess the content of each document and automatically place it in the correct category with a high level of confidence. It significantly reduces the workload of clinical staff, allowing them to focus only on documents that need further review. As a result, the time taken to process these documents has been reduced by up to 25 percent for some clients while still providing “Human in the Loop” verification, leading to substantial cost savings across multiple trials.

The TMF auto-classification tool is just one example of court Square Group’s suite of AI solutions aimed at improving clinical operations. Another is its cross-referencing tool, initially developed for life science mergers and acquisitions but now widely used in clinical settings. When companies acquire new compounds, they must review vast amounts of documentation, ranging from regulatory records to clinical trial data. court Square Group’s cross-referencing tool simplifies the process by automatically reading through all documents, identifying references, and ensuring that nothing is overlooked. It minimizes the time spent in due diligence and reduces the chances of missing critical information, thus speeding up the M&A, In-licensing or Out-licensing new compounds, and clinical trial process.

What sets these tools apart is their adaptability to various tasks across clinical operations. For example, the same AI system that powers the TMF auto-classification tool can be repurposed for submission processes to regulatory bodies like the FDA. By adjusting the learning sets, the AI can identify which regulatory module each document belongs to, expediting the submission process and further improving time-to-market for new drugs.

One of the standout features of court Square Group’s approach to AI is its emphasis on subject matter expertise. Many AI companies focus on theoretical models without fully understanding the unique challenges of the life sciences industry. court Square Group, however, applies its extensive knowledge of clinical research to identify specific pain points and then works backward to develop AI solutions that fit seamlessly into existing workflows.

Looking ahead, court Square Group is focused on expanding its AI solutions into new areas of clinical operations. The company sees potential in extending the capabilities of existing tools to other functions within clinical operations, such as protocol generation and marketing authorization submissions. It is also exploring AI applications that could help central labs collaborate with sponsors and CROs to automate the generation of protocols for drug administration and clinical kits, potentially revolutionizing the way clinical trials are conducted.

Parent’s forward-thinking vision includes expanding the use of Retrieval-Augmented Generation (RAG), an AI technique that pulls information from multiple sources to generate new content, such as clinical trial protocols. These advancements, combined with the company’s deep-rooted understanding of clinical operations, position Court Square to remain at the forefront of AI innovation in the pharmaceutical industry.